Inhibikase Therapeutics, Inc.

Inhibikase Therapeutics, Inc. announced the sale of 25,000,000 shares of its common stock through its at-the-market (ATM) facility to RA Capital Management, generating gross proceeds of $50 million. This capital infusion is expected to fund operations through the topline data readout of the company's global Phase 3 IMPROVE-PAH clinical study, subject to the full exercise of outstanding Series A and B Warrants.

Inhibikase Therapeutics, Inc. announced the grant of non-qualified stock options for an aggregate of 981,243 shares of common stock to seven newly-hired non-executive employees. These grants were made under the Company’s 2026 Inducement Equity Plan, effective June 30, 2026, with an exercise price of $2.03 per share. The options vest 25% on the first anniversary and the remainder in 36 equal monthly installments.

Inhibikase Therapeutics, Inc. held its 2026 Annual Meeting, where stockholders approved an amendment to the 2020 Equity Incentive Plan, increasing the authorized shares reserved for issuance by 3,000,000. Additionally, shareholders approved an amendment to the Certificate of Incorporation to limit the liability of certain officers, elected two Class III directors, and ratified CohnReznick LLP as the independent auditor. Stockholders also approved executive officer compensation on an advisory basis and determined to hold future advisory votes on executive compensation annually.

Inhibikase Therapeutics reported a net loss of $(16.38) million for Q1 2026, an increase from $(13.68) million in Q1 2025. Despite increased operating expenses, the company maintained a strong liquidity position with $170.4 million in cash, cash equivalents, and marketable securities as of March 31, 2026, which is projected to fund operations for at least the next twelve months. The company is currently enrolling patients in its Phase 3 clinical study for IKT-001 for Pulmonary Arterial Hypertension.

Inhibikase Therapeutics announced its first quarter 2026 financial results and significant corporate updates. The company initiated its registrational Phase 3 IMPROVE-PAH study for IKT-001 in Pulmonary Arterial Hypertension (PAH) and enrolled the first patient. Inhibikase also secured European Medicines Agency approval for the Phase 3 study in 12 EU countries, contributing to a total of 16 global country approvals, and submitted an Orphan Drug Designation application to the US FDA for IKT-001. For Q1 2026, the company reported a net loss of $16.4 million, or $0.10 per share, with $170.4 million in cash, cash equivalents, and marketable securities.

Inhibikase Therapeutics announced significant progress in its Phase 3 IMPROVE-PAH study for IKT-001, including the enrollment of the first patient and regulatory approvals in 16 countries, leveraging the new European Medicines Agency FAST-EU initiative. The company also submitted an Orphan Drug Designation application to the US FDA for IKT-001 for Pulmonary Arterial Hypertension. For the first quarter ended March 31, 2026, Inhibikase reported a net loss of $16.4 million, or $0.10 per share, and held $170.4 million in cash, cash equivalents, and marketable securities.

Inhibikase Therapeutics, Inc. announced its 2026 Annual Meeting of Stockholders will be held virtually on June 26, 2026. Key proposals include the election of two Class III directors, ratification of CohnReznick LLP as the independent auditor, and approval of an amendment to the certificate of incorporation to limit officer liability. Stockholders will also vote on increasing the authorized shares for the 2020 Equity Incentive Plan by 3,000,000 shares and advisory votes on executive compensation and its frequency.

Inhibikase Therapeutics has announced the enrollment of the first patient in its global Phase 3 clinical trial, IMPROVE-PAH, evaluating IKT-001 for the treatment of pulmonary arterial hypertension (PAH). This marks a significant milestone in the development of IKT-001 and could be a positive catalyst for the company's stock as it progresses towards potential regulatory approval and commercialization.